evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

65 questions · 65 findings · 8 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 16 · 24.6%GRADE not reported 9 · 13.8%Very low 16 · 24.6%Low 7 · 10.8%Moderate 16 · 24.6%High 1 · 1.5%

Dexamethasone vs betamethasone – child outcomes

Developmental delay –motor (mild, moderate or severe) · women at risk of preterm birth

Dexamethasone showed no clear difference in developmental delay –motor (mild, moderate or severe) compared with betamethasone – child outcomes (moderate certainty).

1 finding from 1 review

Dexamethasone vs betamethasone – child outcomes

Intellectual impairment: developmental delay – cognitive or language (mild, moderate or severe) · women at risk of preterm birth

Dexamethasone showed no clear difference in intellectual impairment: developmental delay – cognitive or language… compared with betamethasone – child outcomes (moderate certainty).

1 finding from 1 review

Dexamethasone vs betamethasone – maternal outcomes

Maternal adverse effects of therapy · women at risk of preterm birth

Dexamethasone showed no clear difference in maternal adverse effects of therapy compared with betamethasone – maternal outcomes (moderate certainty).

1 finding from 1 review

Dexamethasone vs betamethasone – child outcomes

Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth

Dexamethasone showed no clear difference in any known death after randomisation (fetal, neonatal, child, child… compared with betamethasone – fetal/neonatal outcomes (moderate certainty).

1 finding from 1 review

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Primary: investigator‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: investigator‐ rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).

1 finding from 1 review

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Primary: participant‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: participant‐rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).

1 finding from 1 review

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Number of participants with any adverse event (primary tolerability outcome) · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with topical betamethasone dipropionate (moderate certainty).

1 finding from 1 review